...
机译:通过监管科学晶状体晶体晶状体术治疗非酒精性脂肪性肝炎临床试验中临床点肠癌的病例定义
Virginia Commonwealth UniversityRichmond VA;
Pinnacle Clinical ResearchSan Antonio TX;
Division of Gastroenterology &
HepatologyDuke University School of MedicineDurham NC;
Institute of Cellular MedicineNewcastle UniversityNewcastle Upon Tyne United Kingdom;
Department of Pathology Physiology and ImagingUniversity of Paris DiderotClichy France;
Department of Hepatology H?pital BeaujonClichy France;
Center for Drug Evaluation and Research US Food and Drug AdministrationSilver Springs MD;
Division of Liver Disease Icahn School of Medicine at Mount SinaiNew York NY;
Forum for Collaborative ResearchUniversity of California BerkeleyWashington DC;
National Cancer Institute Center for Cancer ResearchBethesda MD;
Genfit CorpCambridge MA;
Division of Gastroenterology and HepatologySaint Louis University School of MedicineSt. Louis MO;
Department of Hepatology and GastroenterologyH?pital Pitié Salpêtrière et Université Pierre et;
Gastroenterology &
Hepatology Unit Bundesinstitut für Arzneimittel und MedizinprodukteBonn Germany;
Forum for Collaborative ResearchUniversity of California BerkeleyWashington DC;
Virginia Commonwealth UniversityRichmond VA;
机译:通过监管科学晶状体晶体晶状体术治疗非酒精性脂肪性肝炎临床试验中临床点肠癌的病例定义
机译:肝硬化前非酒精性脂肪性肝炎的临床终点和适应性临床试验:促进新流行病的发展方法
机译:在儿科非酒精脂肪型肝炎中设计临床试验:患者选择和适当终点的提示
机译:基于临床决策支持系统的非酒精性脱皮性疾病的非侵入性诊断
机译:从床边到台面:非酒精性脱脂性和肝细胞癌的临床,流行病学和分子基础
机译:非酒精性脂肪性肝炎临床研究中通过监管科学的角度纳入和分析终点的病例定义
机译:在儿科非酒精脂肪型肝炎中设计临床试验:患者选择和适当终点的提示
机译:二甲双胍和标准治疗与标准治疗对胰岛素抵抗和非酒精性脂肪性肝炎(NasH)非糖尿病患者单独使用的影响:试验